Fulltext

Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism

Fontana, Pierre ; Goldhaber, Samuel Z. ; Bounameaux, Henri

In: European Heart Journal, 2014, vol. 35, no. 28, p. 1836-1843

Ajouter à la liste personnelle
    Titre
    • Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
    Auteur
    • Fontana, Pierre. Division of Angiology and Haemostasis, Department of Medical Specialties, Faculty of Medicine and University Hospitals of Geneva, 4, Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
    • Goldhaber, Samuel Z.. Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
    • Bounameaux, Henri. Division of Angiology and Haemostasis, Department of Medical Specialties, Faculty of Medicine and University Hospitals of Geneva, 4, Rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Heart Journal, 2014, vol. 35, no. 28, p. 1836-1843. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:290496
    Summary
    Direct oral anticoagulants (DOACs) specifically target factor IIa or Xa and represent a major step forward in the treatment of acute- and long-term prevention of venous thrombo-embolism (VTE). They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring. These antithrombotic agents introduce a new paradigm for the day-to-day management of VTE. Direct oral anticoagulants should streamline the management of most patients with VTE and will facilitate care in the outpatient setting. Nevertheless, it remains uncertain how to select specific DOACs for particular profiles of patients, and the optimal management of bleeding complications is evolving